If women do receive TAVR treatment, they have a lower mortality rate and excellent outcomes compared to SAVR,10 and superior valve performance compared to the SAPIEN™* platform.8
TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.
™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
† Evolut TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.
‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance for Evolut compared to SAPIEN and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.8
§ Better blood flow, or "near-normal transvalvular flow" means that your new heart is operating well and the gradient across your valve is < 20 mmHg%